Written By:
Henry Cremisi, MD, Executive Medical Director, Medical Affairs
Jonathan Kornstein, Vice President, Rare Disease, Pediatrics, & Nephrology
Rare kidney disease development has accelerated in recent years, yet many programs still struggle to produce clear, decisive outcomes. In our recent webinar, De-Risking in Rare Kidney Disease Development: From Gene to Global Trial Execution, Jonathan Kornstein and Dr. Henry Cremisi explored a central reality: strong science alone is not enough. What differentiates successful programs today is the deliberate alignment of biology, trial design, and operational execution from the very beginning.
Biology First, Always
Renal biology is complex and deeply interconnected. Conditions such as IgA nephropathy, lupus nephritis, FSGS, and complement-mediated diseases may appear distinct, yet they often share overlapping immune, hemodynamic, and structural injury pathways. Recognizing these shared mechanisms is essential when designing Phase 2 trials.
The objective is not simply to “detect a signal.” It is to demonstrate credible engagement with disease biology in a way that supports confident decision-making. A positive readout without mechanistic clarity introduces as much risk as a negative one. Phase 2 should reduce uncertainty—not carry it forward.
Precision in Design Protects the Signal
True de-risking requires discipline at the design stage:
- Eligibility criteria should protect the biologic signal, not dilute it with excessive heterogeneity.
- Dose selection must allow the mechanism to fully express itself.
- Endpoints must reflect the disease’s biology and expected timeline of progression.
An underpowered or loosely constructed Phase 2 trial may appear promising while leaving critical questions unresolved. That ambiguity compounds in Phase 3, where both capital and patient exposure increase dramatically.
Clarity begins with intentional design.
Global Strategy as a Stress Test
Global expansion is often framed as a solution to enrollment challenges. In reality, it introduces another layer of complexity. Differences in genetics, background therapy, diagnostic standards, and disease expression can create meaningful variability.
Rather than viewing this variability as noise, it should be treated as a stress test. A biologically real treatment effect should show directional consistency across regions. When results diverge meaningfully by geography, the signal may reflect population effects rather than mechanism. Identifying that early protects both capital and credibility.
Global execution, therefore, is not simply about speed. It is about validating biological truth across diverse real-world settings.
Operational Discipline Protects the Science
Even the most compelling mechanism can falter under operational strain. Overly complex protocols, optimistic feasibility assumptions, and recycled site strategies undermine signal integrity.
Effective execution requires:
- Realistic enrollment modeling
- Trigger-based monitoring
- Thoughtful geographic diversification
- Site selection grounded in data, not habit
Operational planning is not separate from scientific strategy—it is an extension of it. Protecting the biology in real-world conditions demands as much rigor as designing the mechanism itself.
Biomarkers as Tools for Clarity
Biomarkers were highlighted in the discussion not as add-ons, but as instruments of clarity. Used intentionally, they answer specific questions:
- Is the mechanism engaged?
- Is there structural or inflammatory modulation?
- Is the response durable?
In crowded renal landscapes, traditional endpoints alone rarely differentiate early programs. A coherent biologic narrative—supported by targeted biomarker strategy—strengthens internal decision-making, regulatory dialogue, and scientific communication.
Biomarkers should not measure everything. They should illuminate what matters most.
The Core Lesson
Renal programs do not fail simply because trials are slow or complex. They struggle when ambiguity is introduced early—through misaligned assumptions, design gaps, or operational shortcuts.
When biology, execution, and interpretation are deliberately aligned, Phase 2 becomes a decisive learning opportunity rather than a procedural milestone.
Clarity earned early protects both patients and investment. That is the foundation of meaningful de-risking in rare kidney disease development.
To watch the full webinar on-demand, view it here.